Macular Degeneration Treatment Market Size, Share, Trends, Growth Outlook

Macular Degeneration Treatment Market is estimated to increase at a Compounded Annual Growth Rate of 9.2% CAGR over the forecast period from 2024 to 2030

The Macular Degeneration Treatment Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Treatment (Drug, Devices, Surgery), By Route of Administration (Intravenous Route, Intravitreal Route), By Sales Channel (Ambulatory Surgical Centers, Hospitals, Others).

An Introduction to Macular Degeneration Treatment Market in 2024

In 2024, the market for macular degeneration treatment continues to evolve as a critical area of focus in ophthalmology, given the increasing prevalence and burden of age-related macular degeneration (AMD), a leading cause of vision loss and blindness worldwide among older adults. AMD encompasses two main forms dry AMD (non-neovascular) and wet AMD (neovascular), both characterized by progressive degeneration of the macula, the central portion of the retina responsible for sharp, central vision. Treatment approaches for AMD aim to slow disease progression, prevent vision loss, and preserve visual function through various modalities, including intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, laser therapy, photodynamic therapy, and nutritional supplementation with vitamins and antioxidants. Anti-VEGF therapy, which targets abnormal blood vessel growth and leakage in wet AMD, has revolutionized the management of the disease, leading to improved visual outcomes and reduced risk of severe vision loss. Technological advancements in imaging techniques, drug delivery systems, and therapeutic agents continue to drive innovation in AMD treatment, offering the potential for personalized and targeted approaches to disease management. With the aging population and the increasing prevalence of AMD-associated risk factors such as smoking, obesity, and cardiovascular disease, the market for macular degeneration treatment is poised for continued growth and expansion, offering new hope to millions of individuals at risk of vision impairment and blindness.

Market Trend: Advancements in Biologics and Gene Therapies

A prominent trend in the macular degeneration treatment market is the advancements in biologics and gene therapies. Macular degeneration, a leading cause of vision loss among older adults, involves the degeneration of the central part of the retina known as the macula. Recent years have seen significant progress in the development of novel treatment modalities aimed at slowing disease progression and preserving vision. Biologic drugs, such as anti-vascular endothelial growth factor (anti-VEGF) agents, have revolutionized the treatment of neovascular or wet macular degeneration by targeting abnormal blood vessel growth and leakage in the retina. Additionally, gene therapy approaches hold promise for treating certain forms of macular degeneration by delivering therapeutic genes to retinal cells to restore function and prevent further degeneration. These advancements in treatment modalities represent a shift towards personalized and targeted therapies, offering new hope for patients with macular degeneration and driving innovation in the market.

Market Driver: Aging Population and Increasing Disease Burden

A key driver for the macular degeneration treatment market is the aging population and increasing disease burden. Macular degeneration is predominantly a disease of aging, with the risk of developing the condition increasing significantly with age. As the global population ages, particularly in developed countries, the prevalence of macular degeneration is expected to rise, leading to a greater demand for effective treatment options. Additionally, lifestyle factors such as smoking, obesity, and poor diet contribute to the development and progression of macular degeneration, further exacerbating the disease burden. The growing awareness of the impact of macular degeneration on quality of life and independence underscores the need for accessible, safe, and effective treatments to address the rising incidence of this sight-threatening condition, driving market growth and investment in research and development.

Market Opportunity: Development of Long-Acting Therapies and Disease-modifying Agents

An emerging opportunity in the macular degeneration treatment market lies in the development of long-acting therapies and disease-modifying agents. While current treatment options such as intravitreal injections of anti-VEGF drugs have demonstrated efficacy in slowing disease progression and preserving vision, they require frequent administration and monitoring, posing challenges in terms of patient compliance, healthcare resource utilization, and treatment burden. There is an opportunity for pharmaceutical companies and researchers to develop sustained-release formulations, implantable devices, or alternative drug delivery methods that prolong the duration of therapeutic effect and reduce the need for frequent injections. Additionally, there is growing interest in identifying disease-modifying agents that target the underlying mechanisms of macular degeneration, such as inflammation, oxidative stress, and complement dysregulation, with the potential to halt or reverse disease progression. By investing in the development of long-acting therapies and disease-modifying agents, stakeholders in the macular degeneration treatment market can address unmet medical needs, improve treatment outcomes, and enhance patient convenience and adherence, driving innovation and growth in the market.

Macular Degeneration Treatment Market Share Analysis: Wet Age-related Macular Degeneration (AMD) Treatment

The fast-growing segment within the macular degeneration treatment market is the treatment of wet age-related macular degeneration (AMD) via the intravitreal route. This growth is driven by several factors. Firstly, wet AMD represents an advanced and rapidly progressing form of the disease characterized by the growth of abnormal blood vessels beneath the retina, leading to severe vision loss if left untreated. Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, such as ranibizumab, aflibercept, and bevacizumab, have revolutionized the management of wet AMD by effectively inhibiting the growth of these abnormal blood vessels and preserving visual acuity. Additionally, the intravitreal route offers direct delivery of therapeutic agents to the site of action within the eye, maximizing drug concentration while minimizing systemic side effects. Moreover, the expanding elderly population, which is at a higher risk of developing AMD, drives the demand for effective treatment options for wet AMD. Furthermore, advancements in drug development, including the introduction of novel anti-VEGF agents and sustained-release drug delivery systems, further enhance the efficacy and convenience of intravitreal treatments for wet AMD. Overall, the convergence of disease severity, therapeutic innovation, and clinical efficacy positions intravitreal treatment for wet AMD as the fast-growing segment within the macular degeneration treatment market.

Macular Degeneration Treatment Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAerie Pharmaceuticals Inc, Bausch Health Companies Inc, Bayer AG, Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Lineage Cell Therapeutics Inc, MeiraGTx Holdings plc, Novartis AG, Ocugen Inc, ONL Therapeutics, Oxurion NV, PanOptica, Pfizer Inc, Regeneron Pharmaceuticals Inc, REGENXBIO Inc

Macular Degeneration Treatment Market Segmentation

By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Macular Degeneration Treatment Market Companies

Aerie Pharmaceuticals Inc
Bausch Health Companies Inc
Bayer AG
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd
Lineage Cell Therapeutics Inc
MeiraGTx Holdings plc
Novartis AG
Ocugen Inc
ONL Therapeutics
Oxurion NV
PanOptica
Pfizer Inc
Regeneron Pharmaceuticals Inc
REGENXBIO Inc

Reasons to Buy the Macular Degeneration Treatment Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Macular Degeneration Treatment Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Macular Degeneration Treatment Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Macular Degeneration Treatment Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Macular Degeneration Treatment Market Size Outlook, $ Million, 2021 to 2030
3.2 Macular Degeneration Treatment Market Outlook by Type, $ Million, 2021 to 2030
3.3 Macular Degeneration Treatment Market Outlook by Product, $ Million, 2021 to 2030
3.4 Macular Degeneration Treatment Market Outlook by Application, $ Million, 2021 to 2030
3.5 Macular Degeneration Treatment Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Macular Degeneration Treatment Industry
4.2 Key Market Trends in Macular Degeneration Treatment Industry
4.3 Potential Opportunities in Macular Degeneration Treatment Industry
4.4 Key Challenges in Macular Degeneration Treatment Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Macular Degeneration Treatment Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Macular Degeneration Treatment Market Outlook by Segments
7.1 Macular Degeneration Treatment Market Outlook by Segments, $ Million, 2021- 2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others

8 North America Macular Degeneration Treatment Market Analysis and Outlook To 2030
8.1 Introduction to North America Macular Degeneration Treatment Markets in 2024
8.2 North America Macular Degeneration Treatment Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Macular Degeneration Treatment Market size Outlook by Segments, 2021-2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others

9 Europe Macular Degeneration Treatment Market Analysis and Outlook To 2030
9.1 Introduction to Europe Macular Degeneration Treatment Markets in 2024
9.2 Europe Macular Degeneration Treatment Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Macular Degeneration Treatment Market Size Outlook by Segments, 2021-2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others

10 Asia Pacific Macular Degeneration Treatment Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Macular Degeneration Treatment Markets in 2024
10.2 Asia Pacific Macular Degeneration Treatment Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Macular Degeneration Treatment Market size Outlook by Segments, 2021-2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others

11 South America Macular Degeneration Treatment Market Analysis and Outlook To 2030
11.1 Introduction to South America Macular Degeneration Treatment Markets in 2024
11.2 South America Macular Degeneration Treatment Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Macular Degeneration Treatment Market size Outlook by Segments, 2021-2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others
12 Middle East and Africa Macular Degeneration Treatment Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Macular Degeneration Treatment Markets in 2024
12.2 Middle East and Africa Macular Degeneration Treatment Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Macular Degeneration Treatment Market size Outlook by Segments, 2021-2030
By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Aerie Pharmaceuticals Inc
Bausch Health Companies Inc
Bayer AG
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd
Lineage Cell Therapeutics Inc
MeiraGTx Holdings plc
Novartis AG
Ocugen Inc
ONL Therapeutics
Oxurion NV
PanOptica
Pfizer Inc
Regeneron Pharmaceuticals Inc
REGENXBIO Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment
Drug
-Anti-vascular Endothelial Growth Factor
-Dietary Supplements
-Others
Devices
-Glasses
-Contact Lenses
-Others
Surgery
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)